436 related articles for article (PubMed ID: 28825729)
1. A Children's Oncology Group and TARGET initiative exploring the genetic landscape of Wilms tumor.
Gadd S; Huff V; Walz AL; Ooms AHAG; Armstrong AE; Gerhard DS; Smith MA; Auvil JMG; Meerzaman D; Chen QR; Hsu CH; Yan C; Nguyen C; Hu Y; Hermida LC; Davidsen T; Gesuwan P; Ma Y; Zong Z; Mungall AJ; Moore RA; Marra MA; Dome JS; Mullighan CG; Ma J; Wheeler DA; Hampton OA; Ross N; Gastier-Foster JM; Arold ST; Perlman EJ
Nat Genet; 2017 Oct; 49(10):1487-1494. PubMed ID: 28825729
[TBL] [Abstract][Full Text] [Related]
2. Genetic changes associated with relapse in favorable histology Wilms tumor: A Children's Oncology Group AREN03B2 study.
Gadd S; Huff V; Skol AD; Renfro LA; Fernandez CV; Mullen EA; Jones CD; Hoadley KA; Yap KL; Ramirez NC; Aris S; Phung QH; Perlman EJ
Cell Rep Med; 2022 Jun; 3(6):100644. PubMed ID: 35617957
[TBL] [Abstract][Full Text] [Related]
3. Mutations in the SIX1/2 pathway and the DROSHA/DGCR8 miRNA microprocessor complex underlie high-risk blastemal type Wilms tumors.
Wegert J; Ishaque N; Vardapour R; Geörg C; Gu Z; Bieg M; Ziegler B; Bausenwein S; Nourkami N; Ludwig N; Keller A; Grimm C; Kneitz S; Williams RD; Chagtai T; Pritchard-Jones K; van Sluis P; Volckmann R; Koster J; Versteeg R; Acha T; O'Sullivan MJ; Bode PK; Niggli F; Tytgat GA; van Tinteren H; van den Heuvel-Eibrink MM; Meese E; Vokuhl C; Leuschner I; Graf N; Eils R; Pfister SM; Kool M; Gessler M
Cancer Cell; 2015 Feb; 27(2):298-311. PubMed ID: 25670083
[TBL] [Abstract][Full Text] [Related]
4. Subtype-specific FBXW7 mutation and MYCN copy number gain in Wilms' tumor.
Williams RD; Al-Saadi R; Chagtai T; Popov S; Messahel B; Sebire N; Gessler M; Wegert J; Graf N; Leuschner I; Hubank M; Jones C; Vujanic G; Pritchard-Jones K; ;
Clin Cancer Res; 2010 Apr; 16(7):2036-45. PubMed ID: 20332316
[TBL] [Abstract][Full Text] [Related]
5. Loss or oncogenic mutation of DROSHA impairs kidney development and function, but is not sufficient for Wilms tumor formation.
Kruber P; Angay O; Winkler A; Bösl MR; Kneitz S; Heinze KG; Gessler M
Int J Cancer; 2019 Mar; 144(6):1391-1400. PubMed ID: 30367465
[TBL] [Abstract][Full Text] [Related]
6. Chromosomal anomalies at 1q, 3, 16q, and mutations of SIX1 and DROSHA genes underlie Wilms tumor recurrences.
Spreafico F; Ciceri S; Gamba B; Torri F; Terenziani M; Collini P; Macciardi F; Radice P; Perotti D
Oncotarget; 2016 Feb; 7(8):8908-15. PubMed ID: 26802027
[TBL] [Abstract][Full Text] [Related]
7. Multiple mechanisms of MYCN dysregulation in Wilms tumour.
Williams RD; Chagtai T; Alcaide-German M; Apps J; Wegert J; Popov S; Vujanic G; van Tinteren H; van den Heuvel-Eibrink MM; Kool M; de Kraker J; Gisselsson D; Graf N; Gessler M; Pritchard-Jones K
Oncotarget; 2015 Mar; 6(9):7232-43. PubMed ID: 25749049
[TBL] [Abstract][Full Text] [Related]
8. CTNNB1 mutations and overexpression of Wnt/beta-catenin target genes in WT1-mutant Wilms' tumors.
Li CM; Kim CE; Margolin AA; Guo M; Zhu J; Mason JM; Hensle TW; Murty VV; Grundy PE; Fearon ER; D'Agati V; Licht JD; Tycko B
Am J Pathol; 2004 Dec; 165(6):1943-53. PubMed ID: 15579438
[TBL] [Abstract][Full Text] [Related]
9. RNA expression of the WT1 gene in Wilms' tumors in relation to histology.
Miwa H; Tomlinson GE; Timmons CF; Huff V; Cohn SL; Strong LC; Saunders GF
J Natl Cancer Inst; 1992 Feb; 84(3):181-7. PubMed ID: 1311774
[TBL] [Abstract][Full Text] [Related]
10. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
[TBL] [Abstract][Full Text] [Related]
11. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product.
Werner H; Re GG; Drummond IA; Sukhatme VP; Rauscher FJ; Sens DA; Garvin AJ; LeRoith D; Roberts CT
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5828-32. PubMed ID: 8390684
[TBL] [Abstract][Full Text] [Related]
12. A unique subset of low-risk Wilms tumors is characterized by loss of function of TRIM28 (KAP1), a gene critical in early renal development: A Children's Oncology Group study.
Armstrong AE; Gadd S; Huff V; Gerhard DS; Dome JS; Perlman EJ
PLoS One; 2018; 13(12):e0208936. PubMed ID: 30543698
[TBL] [Abstract][Full Text] [Related]
13. Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children's Oncology Group AREN18B5-Q.
Murphy AJ; Cheng C; Williams J; Shaw TI; Pinto EM; Dieseldorff-Jones K; Brzezinski J; Renfro LA; Tornwall B; Huff V; Hong AL; Mullen EA; Crompton B; Dome JS; Fernandez CV; Geller JI; Ehrlich PF; Mulder H; Oak N; Maciezsek J; Jablonowski CM; Fleming AM; Pichavaram P; Morton CL; Easton J; Nichols KE; Clay MR; Santiago T; Zhang J; Yang J; Zambetti GP; Wang Z; Davidoff AM; Chen X
Nat Commun; 2023 Dec; 14(1):8006. PubMed ID: 38110397
[TBL] [Abstract][Full Text] [Related]
14. Origins of DNA methylation defects in Wilms tumors.
Anvar Z; Acurzio B; Roma J; Cerrato F; Verde G
Cancer Lett; 2019 Aug; 457():119-128. PubMed ID: 31103718
[TBL] [Abstract][Full Text] [Related]
15. Somatic mutations in DROSHA and DICER1 impair microRNA biogenesis through distinct mechanisms in Wilms tumours.
Rakheja D; Chen KS; Liu Y; Shukla AA; Schmid V; Chang TC; Khokhar S; Wickiser JE; Karandikar NJ; Malter JS; Mendell JT; Amatruda JF
Nat Commun; 2014 Sep; 2():4802. PubMed ID: 25190313
[TBL] [Abstract][Full Text] [Related]
16. Association of E2F3 expression with clinicopathological features of Wilms' tumors.
An Q; Wang Y; An R; Li Y; Yao T; Zhai B; Sun X
J Pediatr Surg; 2013 Nov; 48(11):2187-93. PubMed ID: 24210184
[TBL] [Abstract][Full Text] [Related]
17. Loss of imprinting of IGF2 is linked to reduced expression and abnormal methylation of H19 in Wilms' tumour.
Steenman MJ; Rainier S; Dobry CJ; Grundy P; Horon IL; Feinberg AP
Nat Genet; 1994 Jul; 7(3):433-9. PubMed ID: 7920665
[TBL] [Abstract][Full Text] [Related]
18. Wilms tumor and the WT1 gene.
Lee SB; Haber DA
Exp Cell Res; 2001 Mar; 264(1):74-99. PubMed ID: 11237525
[TBL] [Abstract][Full Text] [Related]
19. The development of Wilms tumor: from WT1 and microRNA to animal models.
Tian F; Yourek G; Shi X; Yang Y
Biochim Biophys Acta; 2014 Aug; 1846(1):180-7. PubMed ID: 25018051
[TBL] [Abstract][Full Text] [Related]
20. Genomic profiling maps loss of heterozygosity and defines the timing and stage dependence of epigenetic and genetic events in Wilms' tumors.
Yuan E; Li CM; Yamashiro DJ; Kandel J; Thaker H; Murty VV; Tycko B
Mol Cancer Res; 2005 Sep; 3(9):493-502. PubMed ID: 16179496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
